# Bristol-Myers Squibb Q3 2026 Earnings Report

> Bristol-Myers Squibb reports 7% revenue growth with strong pipeline progress and full-year guidance upgrades.
- Title: Bristol-Myers Squibb Q3 2026 Earnings Report · The Motley Fool
- Summary: Bristol-Myers Squibb reports 7% revenue growth with strong pipeline progress and full-year guidance upgrades. Bristol-Myers Squibb reported 7% year-over-year…
- Keywords: bristol myers squibb, bmy, q3 2026, earnings call, revenue, growth portfolio, opdivo, reblozyl, breyanzi, eliquis, celmod, radiopharmaceuticals
- Source: The Motley Fool — https://fool.com/earnings/call-transcripts/2026/10/29/bristol-myers-squibb-bmy-q3-2026-earnings-call-transcript
- Author: Motley Fool Transcribing
- Published: 2026-10-29T17:53:54+00:00
- Read time: 1 min
- Topics: bristol myers squibb, bmy, q3 2026, earnings call, revenue, growth portfolio, opdivo, reblozyl, breyanzi, eliquis, celmod, radiopharmaceuticals
## Q3 Revenue Growth
Bristol-Myers Squibb reported 7% year-over-year revenue growth to $13.1 billion in Q3 2026.
## Growth Portfolio Expansion
Growth portfolio revenue increased 12% to $7.7 billion driven by Reblozyl, Breyanzi, and Opdualag.
## Eliquis Performance
Eliquis revenue reached $4.7 billion, up 26% from favorable pricing and strong market share gains.
## Opdivo Transition
Opdivo revenue decreased 6% as 17% of patients switched to subcutaneous Qvantig formulation.
## Reblozyl Growth
Reblozyl revenue grew 22% to $750 million with increased demand in first-line myelodysplastic syndromes.
## Breyanzi Surge
Breyanzi revenue increased 48% to $526 million due to strong global demand.
## Camzyos Expansion
Camzyos revenue grew 42% to $420 million with deeper community market penetration.
## Sotyktu Growth
Sotyktu revenue increased 26% with new psoriatic arthritis indication approval.
## Cobenfy Performance
Cobenfy revenue grew 33% to $57 million despite inventory drawdown impacts.
## Acquired IPRD Charges
Company recorded $1.6 billion in acquired in-process research and development charges.
## Full-Year Guidance
Raised full-year revenue guidance to $49.75 billion to $50.25 billion with non-GAAP EPS of $6.35 to $6.55.
## Manufacturing Investments
Investing $2.3 billion in Houston campus and $173 million in Indiana radiopharmaceutical expansion.
## Productivity Initiative
Targeting $2 billion in efficiency savings by end of 2027 through operational improvements.
## Eliquis LOE Impact
Anticipating $1.5 billion to $2 billion revenue step down for Eliquis in 2027 due to European patent expiration.
## Symvexis Launch
Symvexis, first approved CELMoD, achieved positive early launch feedback with strong Phase 3 data.
## Pipeline Progress
Multiple Phase 3 results expected for Milvexian in stroke prevention and Sotyktu in lupus by year end.
## Key takeaway

Bristol-Myers Squibb reported 7% year-over-year revenue growth to $13.1 billion in Q3 2026, with 8 growth portfolio medicines annualizing over $1 billion each.